Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A

Neoplasia (United States)

Volumn 15, Issue 2, 2013, Pages 112-124

  Lee, Esak ^a,b   Koskimaki, Jacob E ^a   Pandey, Niranjan B ^a   Popel, Aleksander S ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Whiting School of Engineering   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; GROWTH HORMONE; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; NEUROPILIN 1; NEUROPILIN 2; PEPTIDE SP5031; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPH NODE; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84873489315     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121638     Document Type: Article

References (38)

1. Carmeliet P and Jain RK (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307.
2. Tammela T and Alitalo K (2010). Lymphangiogenesis: molecular mechanisms and future promise. Cell 140, 460-476.
3. Doeden K, Ma Z, Narasimhan B, Swetter SM, Detmar M, and Dadras SS (2009). Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol 36, 772-780.
4. Lee AH, Pinder SE, Macmillan RD, Mitchell M, Ellis IO, Elston CW, and Blamey RW (2006). Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 42, 357-362.
5. Hyung WJ, Lee JH, Choi SH, Min JS, and Noh SH (2002). Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol 9, 562-567.
6. Ran S, Volk L, Hall K, and Flister MJ (2010). Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 17, 229-251.
7. Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, Moch H, and Detmar M (2010). Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol 177, 1004-1016.
8. Tobler NE and Detmar M (2006). Tumor and lymph node lymphangiogenesis- impact on cancer metastasis. J Leukoc Biol 80, 691-696.
9. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, and Detmar M (2007). VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109, 1010-1017.
10. Duong T, Koopman P, and Francois M (2012). Tumor lymphangiogenesis as a potential therapeutic target. J Oncol 2012, 204946.
11. DeSantis C, Siegel R, Bandi P, and Jemal A (2011). Breast cancer statistics, 2011. CA Cancer J Clin 61, 409-418.
12. Doyle DM and Miller KD (2008). Development of new targeted therapies for breast cancer. Breast Cancer 15, 49-56.
13. Kerbel RS (2011). Reappraising antiangiogenic therapy for breast cancer. Breast 20(suppl 3), S56-S60.
14. Martin M (2011). Understanding the value of antiangiogenic therapy in meta-static breast cancer. Curr Opin Oncol 23(suppl), S1.
15. Tanne JH (2011). FDA cancels approval for bevacizumab in advanced breast cancer. BMJ 343, d7684.
16. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, and Casanovas O (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231.
17. Ribatti D (2011). Antiangiogenic therapy accelerates tumor metastasis. Leuk Res 35, 24-26.
18. Karagiannis ED and Popel AS (2008). A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci USA 105, 13775-13780.
19. Lee E, Rosca EV, Pandey NB, and Popel AS (2011). Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Int J Biochem Cell Biol 43, 1812-1821.
20. Tomayko MM and Reynolds CP (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24, 148-154.
21. Mumprecht V and Detmar M (2009). Lymphangiogenesis and cancer metastasis. J Cell Mol Med 13, 1405-1416.
22. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, and Detmar M (2005). VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201, 1089-1099.
23. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, et al. (2008). Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13, 331-342.
24. Kawamura H, Li X, Goishi K, van Meeteren LA, Jakobsson L, Cebe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, et al. (2008). Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112, 3638-3649.
25. Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Heroult M, Augustin HG, Ponta H, et al. (2009). A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood 114, 5236-5244.
26. Forster-Horvath C, Meszaros L, Raso E, Dome B, Ladanyi A, Morini M, Albini A, and Timar J (2004). Expression of CD44v3 protein in human endothelial cells in vitro and in tumoral microvessels in vivo. Microvasc Res 68, 110-118.
27. Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, and Koizumi F (2011). Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 13, R66.
28. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26, 127-132.
29. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, and Lala PK (2012). Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 92, 1115-1128.
30. Shibata MA, Morimoto J, Shibata E, and Otsuki Y (2008). Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther 15, 776-786.
31. Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, Arimura Y, Endo T, Lee CT, Carbone DP, et al. (2011). Insulin-like growth factor-I receptor block-ade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer 117, 3135-3147.
32. Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, and Popel AS (2011). Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 12, 1101-1116.
33. Carlini MJ, De Lorenzo MS, and Puricelli L (2011). Cross-talk between tumor cells and the microenvironment at the metastatic niche. Curr Pharm Biotechnol 12, 1900-1908.
34. Koskimaki JE, Lee E, Chen W, Rivera CG, Rosca EV, Pandey NB, and Popel AS (2012). Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors. Angiogenesis 16, 159-170.
35. Bagri A, Tessier-Lavigne M, and Watts RJ (2009). Neuropilins in tumor biology. Clin Cancer Res 15, 1860-1864.
36. Spratlin J (2011). Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 13, 97-102.
37. Nguyen A, Chen P, and Cai H (2004). Role of CaMKII in hydrogen peroxide activation of ERK1/2, p38 MAPK, HSP27 and actin reorganization in endothelial cells. FEBS Lett 572, 307-313.
38. Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, and Horwitz KB (2006). Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 66, 9308-9315.